Bli medlem
Bli medlem

Du är här

2020-03-12

AstraZeneca: Notice of Annual General Meeting

AstraZeneca PLC (the Company) announced today the publication of its
Notice of Annual General Meeting 2020 and Shareholders' Circular (the
Notice).

The Notice has been submitted to the National Storage Mechanism and
will shortly be available for inspection at
www.morningstar.co.uk/uk/nsm. The Notice is also available on the
Company's website at www.astrazeneca.com/agm.

The Company's Annual Report and Form 20-F Information 2019 was
published on 3 March 2020.

The Notice is being despatched to shareholders today.

The meeting place for the Annual General Meeting (AGM) will be
Leonardo Royal Hotel London Tower Bridge, 45 Prescot St, London, E1
8GP and the AGM will commence at 2.30 pm (BST) on 29 April 2020.

The Company continues to monitor the situation in relation to COVID-19
and will notify shareholders via our website, www.astrazeneca.com as
soon as practicably possible if there are any changes to the AGM
arrangements. Shareholders are reminded of their right to appoint
the Chairman of the AGM, or any other person, as their proxy to
attend the meeting and vote on their behalf.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery, development
and commercialisation of prescription medicines, primarily for the
treatment of diseases in three therapy areas - Oncology,
Cardiovascular, Renal and Metabolism, and Respiratory. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow
the Company on Twitter @AstraZeneca
(https://twitter.com/AstraZeneca).

Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Angela Fiorin BioPharmaceuticals +44 1223 344 690
Jennifer Hursit Other +44 203 749 5762
Christina Sweden +46 8 552 53 106
Malmberg
Hägerstrand
Michele Meixell US +1 302 885 2677
Investor
Relations
Thomas Kudsk +44 203 749 5712
Larsen
Henry Wheeler Oncology +44 203 749 5797
Christer BioPharmaceuticals +44 203 749 5711
Gruvris (Cardiovascular, Metabolism)
Nick Stone BioPharmaceuticals (Renal) +44 203 749 5716
Environmental, Social and
Governance
Josie Afolabi BioPharmaceuticals +44 203 749 5631
(Respiratory)
Tom Waldron Other medicines +44 7385 033 717
Craig Marks Finance Fixed income +44 7881 615 764
Jennifer Corporate access Retail +44 203 749 5824
Kretzmann investors
US toll-free +1 866 381 72 77

Christina Malmberg Hägerstrand
Presschef AstraZeneca AB och Norden Baltikum
+ 46 8 552 53 106
christina.malmberghagerstrand@astrazeneca.com

-----------------------------------------------------------
https://news.cision.com/se/astrazeneca/r/notice-of-annual-general-meetin...

Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.